A number of firms have modified their ratings and price targets on shares of Enanta Pharmaceuticals (NASDAQ: ENTA) recently:

  • 8/8/2018 – Enanta Pharmaceuticals was downgraded by analysts at UBS Group AG from an “outperform” rating to a “market perform” rating.
  • 8/8/2018 – Enanta Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “hold” rating. They now have a $100.00 price target on the stock.
  • 7/31/2018 – Enanta Pharmaceuticals had its “buy” rating reaffirmed by analysts at JMP Securities. They now have a $120.00 price target on the stock.
  • 7/26/2018 – Enanta Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 7/25/2018 – Enanta Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $126.00 price target on the stock. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 7/24/2018 – Enanta Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/4/2018 – Enanta Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 6/22/2018 – Enanta Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/15/2018 – Enanta Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of NASDAQ ENTA traded down $5.46 during mid-day trading on Wednesday, hitting $86.30. The company’s stock had a trading volume of 16,062 shares, compared to its average volume of 311,155. The firm has a market capitalization of $1.93 billion, a PE ratio of 94.84 and a beta of 0.92. Enanta Pharmaceuticals Inc has a one year low of $37.13 and a one year high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.98 by ($0.01). The business had revenue of $57.26 million during the quarter, compared to the consensus estimate of $56.59 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. equities research analysts expect that Enanta Pharmaceuticals Inc will post 3.36 EPS for the current year.

In other news, insider Jay R. Luly sold 25,000 shares of the firm’s stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $105.83, for a total value of $2,645,750.00. Following the transaction, the insider now owns 638,994 shares of the company’s stock, valued at approximately $67,624,735.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of the firm’s stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $105.25, for a total transaction of $437,313.75. Following the completion of the transaction, the vice president now directly owns 8,955 shares in the company, valued at approximately $942,513.75. The disclosure for this sale can be found here. Insiders sold a total of 88,355 shares of company stock worth $10,382,033 in the last ninety days. Insiders own 10.56% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Meadow Creek Investment Management LLC bought a new position in Enanta Pharmaceuticals during the 1st quarter worth approximately $110,000. SG Americas Securities LLC bought a new position in Enanta Pharmaceuticals during the 1st quarter worth approximately $112,000. Riverhead Capital Management LLC bought a new position in Enanta Pharmaceuticals during the 1st quarter worth approximately $129,000. Glen Harbor Capital Management LLC bought a new position in Enanta Pharmaceuticals during the 1st quarter worth approximately $140,000. Finally, Sei Investments Co. boosted its stake in Enanta Pharmaceuticals by 63,966.7% during the 1st quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 1,919 shares during the last quarter. 77.01% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Recommended Story: New Google Finance Tool and Screening Stocks

Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.